Natural history of cardiovascular and renal disease in patients with type 2 diabetes: Effect of therapeutic interventions and risk modification

American Journal of Cardiology

Volumn 82, Issue 9 SUPPL. 1, 1998, Pages 4-8

  Mogensen, Carl Erik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HISTORY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY DISEASES; RISK; RISK FACTORS;

EID: 0032512106     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00749-8     Document Type: Article

References (60)

1. Krolewski AS, Warram JH. Natural history of diabetic nephropathy. How much can it be changed? Diabetes Rev 1995;3:446-.
2. Fuller JH, Head J, WHO Multinational Study Group. Blood pressure, protein-uria and their relationship with circulatory mortality: the WHO multinational study of vascular disease in diabetics. Diabet Metab (Paris) 1989;15:273-277.
3. Fuller JH, Stevens LK. Epidemiology of hypertension in diabetic patients and implications for treatment. Diabetes Care 1991;14(suppl 4):8-12.
4. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease and stroke mortality by degree of glycaemia: the Whitehall Study. Br Med J 1983; 287:867-870.
5. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886-1892 [erratum JAMA 1997;277:1356].
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
7. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384-394.
8. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97:1436-1439.
9. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR, for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998;316: 823-828.
10. Gæde P, Vedel P, Parving HH, Pedersen O. The Steno type 2 study: Intensive multifactorial intervention delays progression in diabetic micro- and macroangiopathy in microalbuminuric type 2 diabetic patients. (Abstr.) Diabetologia 1998; 41(suppl):A7.
11. Yudkin JS. How can we best prolong life? The benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. Br J Med 1993;306:1313-1318.
12. Mogensen CE. Microalbuminuria in maturity onset, primarily type 2 (non-insulin-dependent) diabetes, predicts clinical proteinuria and early mortality. (Abstr.) Diabetologia 1983:181.
13. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360.
14. Dinneen S, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-1418.
15. Mogensen CE, Hansen KW, Osterby R, Damsgaard EM. Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care 1992;15:1192-1204.
16. Cooper M, McNally P. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus, 4th ed. Holland: Kluwer Academic Publishers, 1998:419-434.
17. Donnelly R, Molyneaux LM, Wileyn KA, Yue DK. Comparative effects of indapamide and captopril in diabetic microalbuminuria. Am J Cardiol 1996; 77(suppl):26B-30B.
18. Bianchi S, Bigazzi R, Baldari I, Campese VM. Microalbuminuria in patients with essential hypertension: effects of several antihypertensive agents. Am J Med 1992;93:525-528.
19. Redon J. Treatment of patients with essential hypertension and microalbuminuria. Drugs 1997;54:857-866.
20. Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993;21:810-815.
21. Agrawal B, Wolf K, Berger A, Luft FC. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996;10:551-555.
22. Pettitt DJ, Knowler WC, Nelson RG. Familial factors in diabetic nephropathy. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus. 4th ed. Holland: Kluwer Academic Publishers, 1998:103.
23. Fagerudd JA, Tarnow L, Jacobsen P, Stenman S, Nielsen FS, Pettersson-Fernholm KJ, Gronhagen-Riska C, Parving HH, Groop PH. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998;47:439-444.
24. Rudberg S, Stattin EL, Dahlquist G. Familial and perinatal risk factors for micro- and macroalbuminuria in young IDDM patients. Diabetes 1998;47:1121-1126.
25. Olivarius de FN, Andreasen AH, Keiding N, Mogensen CE. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice," Denmark. Diabetologia 1993;36:1007-1016.
26. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 1998;21:S20-S22.
27. Alberti KGMM, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of WHO Consultation. Diabetic Med 1998;15:539-553.
28. Mogensen CE, Mau Pedersen M, Ebbehoj E, Poulsen PL, Schmitz A. Combination therapy in hypertension-associated diabetic renal disease. Int J Clin Prac 1997;suppl 90:52-58.
29. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 1998;21:116-120.
30. Forsblom CM, Groop P-H, Ekstrand A, et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998. In press.
31. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158:134-140.
32. Schmitz A. Microalbuminuria, blood pressure, metabolic control, and renal involvement. Longitudinal studies in white non-insulin-dependent diabetic patients. Am J Hypertens 1997;10:189S-197S.
33. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998;21:S5-S20.
34. Parving HH. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998;41:745-759.
35. Nielsen FS, Sato A, Ali S, Tarnow L, Smidt UM, Kastrup J, Parving HH. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. Diabetes Care 1998;21:804-809.
36. Lambert J, Smulders RA, Aarsen M, Donker JM, Stehouwer CDA. Carotid artery stiffness is increased in microalbuminuric IDDM patients. Diabetes Care 1998;21:99-103.
37. Eibl N, Schnack CH, Frank M, Schernthaner G. Initial urinary albumin excretion determines the progression of microalbuminuria in patients with type 2 diabetes and normotensive blood pressure values despite improved metabolic control. Diab Res Clin Pract 1998;39:39-45.
38. Weir MR, Dworkin LD. Antihypertensive drugs, dietary salt, and renal protection: How low should you go and with which therapy? Am J Kidney Dis 1998;32:1-22.
39. Islam N, Kazmi F, Chusney G, Mattock MB, Zaini A, Pickup JC. Ethnic differences in correlates of microalbuminuria in NIDDM. Diabetes Care 1998; 21:385-388.
40. Sawicki PT, Kiwitt S, Bender R, Berger M. The value of QT interval dispersion for identification of total mortality risk in non-insulin-dependent diabetes mellitus. J Intern Med 1998;243:49-56.
41. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med 1998;128:982-988.
42. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351: 1755-1762.
43. Pontremoli R, Nicolella C, Viazzi F, Ravera M, Sofia A, Berruti V, Bezante GP, Del Sette M, Martinoli C, Sacchi G, Defarrari G. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1997;11:430-438.
44. Florkowski CM, Scott RS, Moir CL, Graham PJ. Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. Diabetic Med 1998;15:386-392.
45. Guillausseau PJ, Massin P, Charles MA, Allaguy H, Guvenli Z, Virally M, Tielmans D, Assayag M, Warnet A, Lubetzki J. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabet Med 1998;15:151-155.
46. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997;20:1767-1773.
47. Yudkin JS. Factors influencing threshold and choice of treatment for hypertension in NIDDM. Diabetes Care 1991;14:27-32.
48. Uusitupa J, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175-1184.
49. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-967.
50. Andersson DK, Svardsudd K. Long-term glycemic control relates to mortality in type 2 diabetes. Diabetes Care 1995;18:1534-1543.
51. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44:1303-1309.
52. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996;39:1540-1545.
53. Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27:63-68.
54. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish Studies. Ann Intern Med 1996;124:127-130.
55. Kohner EV. Diabetic retinopathy and high blood pressure: defining the risk. Am J Hypertens 1997;10:181S-183S.
56. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-219.
57. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713.
58. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;327:713-720.
59. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:839-855.
60. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:856-867.